BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.665
-0.023 (-3.399%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.688
Open0.680
Bid0.630 x 10000
Ask0.899 x 500
Day's Range0.630 - 0.688
52 Week Range0.600 - 2.760
Volume581,797
Avg. Volume743,875
Market Cap23.397M
Beta2.32
PE Ratio (TTM)N/A
EPS (TTM)-0.868
Earnings DateMar 5, 2018 - Mar 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Scientists seek super-shot for flu 100 years after pandemic
    Associated Press3 days ago

    Scientists seek super-shot for flu 100 years after pandemic

    WASHINGTON (AP) — The descriptions are haunting.

  • Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
    PR Newswire11 days ago

    Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers

    SAN DIEGO, Jan. 9, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the Company's Target Selector™ ctDNA lung cancer assays improves detection of key lung cancer mutations.  Data from 3,000 samples analyzed using Biocept's liquid biopsy assays for EGFR, BRAF and KRAS mutations demonstrated single mutant copy detection on the QS5 platform with more than 99% sensitivity and more than 99% specificity.

  • Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
    PR Newswire16 days ago

    Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of Australian Patent No. 2012250516, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. This is the second issued patent for Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next generation sequencing (NGS).

  • Capital Cube23 days ago

    ETFs with exposure to Biocept, Inc. : December 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlaxoSmithKline (Egypt): Strong price momentum but will it sustain?
    Capital Cubelast month

    GlaxoSmithKline (Egypt): Strong price momentum but will it sustain?

    Categories: Yahoo FinanceGlaxoSmithKline (Egypt) relative valuation is OVERVALUED and it has a fundamental analysis score of 47. Our analysis is based on comparing GlaxoSmithKline (Egypt) with the following peers – Egyptian International Pharmaceutical Industries Co., Arab Drug Company for Pharmaceuticals and Chemi cal Industries, May & Baker Nigeria Plc and Memphis Pharmaceutical & Chemical Industries (PHAR-EG, ADCI-EG, ... Read more (Read more...)

  • PR Newswirelast month

    Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota

    SAN DIEGO, Dec. 18, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has signed an in-network provider agreement with Wellmark, Inc., the largest health insurer in Iowa and South Dakota.

  • Capital Cubelast month

    ETFs with exposure to Biocept, Inc. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • SmarterAnalystlast month

    What Spooked Biocept Inc (BIOC) Investors Today

    The biotech firm priced 4,925,936 shares at $ $0.68 apiece, which was well below the $1.15 per share where the stock had been trading yesterday afternoon. In addition to that deep discount, the offering represents nearly 20% dilution for existing shareholders. No warrants to purchase shares of the Company's common stock will be issued to the investors in connection with the offering. Dawson James Securities, Inc. and WestPark Capital, Inc. acted as placement agents in connection with the offering, with Dawson James Securities, Inc. acting as the lead placement agent.  In connection with the offering, the Company has agreed to issue Dawson James Securities, Inc. a warrant, exercisable beginning in six months, to purchase 246,296 shares of the Company's common stock with an exercise price equal to $0.85 per share.

  • Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock
    PR Newswirelast month

    Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock

    SAN DIEGO , Dec. 6, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians ...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.

    NEW YORK, NY / ACCESSWIRE / December 6, 2017 / A surprise patent win for Biocept help shares climb to a close of 70% in gains while positive phase 2 clinical data on its NSI-189 drug helped Neuralstem ...

  • SmarterAnalyst2 months ago

    Biocept Inc Shares Skyrocket on Surprise Patent Victory

    On Tuesday, the tiny-size drug maker stunned Wall Street with the issuance of key US patent covering the company's proprietary "switch-blocker" technology. Biocept shares are skyrocketing nearly 65% on the news. The technology enriches patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer-associated mutations.

  • First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
    PR Newswire2 months ago

    First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform

    SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of U.S. Patent No. 9,834,817, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.

  • Capital Cube2 months ago

    ETFs with exposure to Biocept, Inc. : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube2 months ago

    Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Biocept, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Biocept, Inc. – Genomic Health, Inc., Exact Sciences Corporation, Vermillion, Inc., Myriad Genetics, Inc., Foundation Medicine, Inc., Trovagene, Inc. and Veracyte Inc (GHDX-US, EXAS-US, VRML-US, MYGN-US, FMI-US, TROV-US and ... Read more (Read more...)

  • Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
    PR Newswire2 months ago

    Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy

    SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces entering into a clinical study agreement with the University of California San Diego (UCSD) Medical Center. Led by recognized immune-oncology and precision medicine specialist Sandip Patel, M.D., Assistant Professor at UCSD School of Medicine, the 100-patient study is designed to clinically validate Biocept's Target Selector™ PD-L1 assay for patients diagnosed with non-small cell lung cancer (NSCLC).

  • Capital Cube2 months ago

    ETFs with exposure to Biocept, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biocept Reports Third Quarter 2017 Financial Results
    PR Newswire2 months ago

    Biocept Reports Third Quarter 2017 Financial Results

    -- Despite the impact from natural disasters and fewer sales days, revenues were up 6% and 111% in 3Q 2017 and year to date, respectively, versus the prior-year periods inclusive of the impact of conversion ...

  • ACCESSWIRE2 months ago

    Biocept, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Biocept, Inc. (NASDAQ: BIOC ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM Eastern Time. ...

  • Capital Cube3 months ago

    ETFs with exposure to Biocept, Inc. : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017
    PR Newswire3 months ago

    Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017

    SAN DIEGO , Nov. 2, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...

  • Capital Cube3 months ago

    ETFs with exposure to Biocept, Inc. : October 23, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board
    PR Newswire3 months ago

    Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center. "We welcome Dr. Hirsch to our Clinical Advisory Board and look forward to benefitting from his significant expertise in lung cancer," said Biocept's President and Chief Executive Officer Michael Nall.  "Dr. Hirsch is a prominent figure in the clinical and academic communities focused on lung cancer, and has received numerous awards and authored hundreds of peer-reviewed papers.  He is involved in studies of lung cancer diagnosis, staging, prevention, early detection and treatment that have favorably impacted the care of lung cancer patients, and his research has helped to identify and validate predictive markers for personalized lung cancer therapies.

  • Capital Cube3 months ago

    ETFs with exposure to Biocept, Inc. : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What You Must Know About Biocept Inc’s (BIOC) Risks
    Simply Wall St.4 months ago

    What You Must Know About Biocept Inc’s (BIOC) Risks

    If you are a shareholder in Biocept Inc’s (NASDAQ:BIOC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube4 months ago

    Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Biocept, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1.28 million, Net Earnings of USD -5.69 million. Gross margins widened from -151.87% to -85.21% compared to the same period last year, operating (EBITDA) margins now -419.62% from -671.60%. Change in operating cash ... Read more (Read more...)